Acelot, Inc.
South San Francisco, United States
FOR BUSINESS DEVELOPMENT, LICENSING & INVESTMENT
South San Francisco, United States

Ticker: CGTX
Purchase, United States
Cognition Therapeutics, Inc. ($CGTX) is a clinical-stage biopharmaceutical company with 20 years of mechanistic, translational, and clinical research across neurodegenerative diseases. Zervimesine (CT1812) is an investigational, first-in-class oral therapy with a unique disease-modifying mechanism of action that displaces toxic protein oligomers from neuronal receptors.
The company has prioritized development of zervimesine in dementia with Lewy bodies (DLB). Cognition and the U.S. FDA have reached alignment on key elements of a Phase 3 study in DLB including patient selection, dose, duration, and endpoints. The company expects to commence the study mid-2027. Cognition plans to use a neuropsychiatric inventory that measures hallucinations and delusions (NPI‑2) as a primary endpoint. A key secondary endpoint will be the ADCS-ADL, which will evaluate zervimesine’s treatment impact on daily function.

United States
United States

Kensington, United States
Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies for serious brain and retinal diseases.
Lead program, GAL-101 (eye drops), is in a Phase 2 trial for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration (dAMD). An oral formulation of GAL-101 has successfully completed Phase 1 testing and shown to be safe, well tolerated, and effectively crosses the blood-brain barrier. Target engagement could be shown. Phase 2 trials in Alzheimer’s (oral) and glaucoma (eye drops) are planned. A next-generation compound, GAL-301, is in pre-clinical testing.
Galimedix is looking for crossover financing to progress GAL-101 to clinical proof of concept in Alzheimer´s disease and to advance its earlier-stage programs ahead of a planned US IPO.
Galimedix has signed a licensing and equity deal with Théa Open Innovation for co-development and commercial rights to GAL-101 in ophthalmology, excluding APAC and is pursuing additional regional partnerships.
Recent highlights include the successful completion of the first-in-human study of the oral version of GAL-101, data presented at CTAD, and the ongoing Phase 2 eDREAM trial in GA, with LPI anticipated this year.


Frankfurt, Germany
Merz Therapeutics is a global specialty neurology biopharma focused development and commercialization of movement disorders, neurodegenerative disorders, rare/orphan neurological disease and chronic pain. We actively seek clinical and commercial opportunities including for in-licensing and M&A.

MATARO, Spain
St paul, United States
Spain
United States
Cupertino, United States
Switzerland
Switzerland

Aarhus, Denmark

Australia
United Kingdom
United States
Pasadena, United States
United States

Ticker: ENVB
Cambridge, United States
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders.


Oxford, United Kingdom

McLean, United States
Camberwell, Australia
Cambridge, United States

Boston, United States
Mosaica Medicines is developing a completely novel non-ion-channel mechanism for epilepsy, with disease modifying potential. The biological hypothesis is based on a large body of evidence showing the RAS/MAPK pathway is:
- A master regulator of CNS hyperexcitability and gene expression of ion channels
- Hyperactivated in the brain in the context of epilepsy/seizures
- Associated with epilepsy in human genetic contexts (both somatic and germline variants)
On the basis of this biology as well as clinical case reports showing dramatic seizure reductions with poorly-brain-penetrant MEK inhibitors (limited by systemic tolerability), Mosaica acquired a highly brain-penetrant MEK inhibitor which will be developed in two distinct epilepsy populations. The company has generated data in gold-standard epilepsy mouse models showing clear dose-dependent reduction of spontaneous seizures at ultra-low doses, which should provide a significant therapeutic window in the clinic.
The program is Phase 1 ready (open IND) and the company has put together a team with significant epilepsy experience to execute on the clinical program, including CMO Brad Galer (previously CMO at two epilepsy companies, Rapport Tx and Zogenix) as well as a SAB that includes the lead Phase 3 investigators of every epilepsy drug approved in the last decade. Doug Williams (former Head of R&D at Biogen) has also joined as independent BoD member. Lux Capital led the founding investment in the company and has invested the majority of the $9.3M capital raised to date. Mosaica is now raising an $80M Series A to fund the company through two Phase 2 PoC trials in epilepsy patients.

Sewickley, United States

Gosselies, Belgium


Tampa, United States
Psilera is a biopharmaceutical company developing groundbreaking therapeutics for CNS disorders.
Psilera has built a leading pipeline of next-generation neuroplastogens, including PSIL-006, a first-in-class therapeutic neuroplastogen.
With a deep commitment to scientific excellence and patient centricity, Psilera strives to provide treatment options to underserved patient populations worldwide. Welcome to the new era of mindful medicine. For more information, visit www.psilera.com.

United States
Toronto, Canada
Houston, United States
Switzerland
United States
Beijing , China
Alken, Belgium

Westfield, United States
